Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Azithromycin

FDA-approved product (capsule, oral), marketed as Azasite, Azithromycin, Zithromax and 1 more.

Registered studies
50+
Lab records
20
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Azithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Cervicitis
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Eye infection
  • HIV infection
  • Infection
  • Infectious otitis media
  • Otitis media
  • Pelvic Inflammatory Disease
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis
  • and 2 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA10; WHO ATC S01AA26

Repurposing investigation

Azithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli89.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae88.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 7 of 9 lab records
  • E. coli: measured active in 3 of 3 lab records
  • K. pneumoniae: measured active in 8 of 8 lab records
Open Azithromycin in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Azithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE

    NCT07641348 · start 2026-07-01

    Registered record
    Registry ID
    NCT07641348
    Conditions
    Typhoid Fever
    Interventions
    meropenem; Meropenem and azithromycin combination
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2027-02-01
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTyphoid Fever
    Interventionmeropenem; Meropenem and azithromycin combination
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Azithromycin and Ampicillin for Late PPROM

    NCT07183462 · start 2025-09-10

    Registered record
    Registry ID
    NCT07183462
    Conditions
    Pregnancy Complications, Infectious; Premature Birth; Neonatal Diseases and Abnormalities; Antibiotic Prophylaxis; Latency Period; Prematurity
    Interventions
    Intravenous Ampicillin followed by Oral Amoxicillin; Ampicillin/Amoxicillin plus single-dose PO Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-09-10
    Completion
    2029-07-31
    Enrolment
    311

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy Complications, Infectious; Premature Birth; Neonatal Diseases and Abnormalities; Antibiotic Prophylaxis +2 more
    InterventionIntravenous Ampicillin followed by Oral Amoxicillin; Ampicillin/Amoxicillin plus single-dose PO Azithromycin
    PhasePhase 4
    Registry statusRecruiting

  • Individualizing Treatment for Asthma in Primary Care (Full Study)

    NCT07052942 · start 2025-08-01

    Registered record
    Registry ID
    NCT07052942
    Conditions
    Asthma; Asthma Attack; Asthma Exacerbations
    Interventions
    Inhaled corticosteroid (ICS); Azithromycin; Asthma Symptom Monitoring Web-based Application
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2029-11-15
    Enrolment
    3,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Asthma Attack; Asthma Exacerbations
    InterventionInhaled corticosteroid (ICS); Azithromycin; Asthma Symptom Monitoring Web-based Application
    PhasePhase 4
    Registry statusRecruiting

  • Azithromycin Reduction to Reach Elimination of Trachoma B

    NCT06289647 · start 2024-10

    Registered record
    Registry ID
    NCT06289647
    Conditions
    Trachoma
    Interventions
    Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2024-10
    Completion
    2029-08-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrachoma
    InterventionAzithromycin
    PhasePhase 4
    Registry statusWithdrawn

  • Azithromycin Before Induction

    NCT06543290 · start 2023-08-07

    Registered record
    Registry ID
    NCT06543290
    Conditions
    Infections
    Interventions
    Azithromycin Pill; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-08-07
    Completion
    2026-08-07
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionAzithromycin Pill; Placebo
    PhasePhase 1
    Registry statusRecruiting

  • Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria

    NCT05473234 · start 2022-10-06

    Registered record
    Registry ID
    NCT05473234
    Conditions
    Severe Acute Malnutrition
    Interventions
    Azithromycin; Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-10-06
    Completion
    2023-11-29
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Acute Malnutrition
    InterventionAzithromycin; Amoxicillin
    PhasePhase 3
    Registry statusTerminated

  • Efficacy of Azithromycin Plus Doxycycline Versus Doxycycline Plus Placebo in Patients With Rocky Mountain Spotted Fever

    NCT05398055 · start 2022-05-12

    Registered record
    Registry ID
    NCT05398055
    Conditions
    Rocky Mountain Spotted Fever
    Interventions
    Azithromycin + Doxycycline; Placebo + Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-05-12
    Completion
    2025-12-31
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRocky Mountain Spotted Fever
    InterventionAzithromycin + Doxycycline; Placebo + Doxycycline
    PhasePhase 3
    Registry statusUnknown

  • Effect of Azithromycin on Failure Proportion of Severe Periodontitis Non-surgical Treatment

    NCT04198649 · start 2021-11-02

    Registered record
    Registry ID
    NCT04198649
    Conditions
    Severe Chronic Periodontitis
    Interventions
    Non-surgical periodontal treatment and azithromycin treatment; Non-surgical periodontal treatment and placebo treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-11-02
    Completion
    2023-11-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Chronic Periodontitis
    InterventionNon-surgical periodontal treatment and azithromycin treatment; Non-surgical periodontal treatment and placebo treatment
    PhasePhase 3
    Registry statusTerminated

  • Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

    NCT04617626 · start 2020-11-20

    Registered record
    Registry ID
    NCT04617626
    Conditions
    Child Mortality; Azithromycin
    Interventions
    Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-11-20
    Completion
    2021-01-31
    Enrolment
    1,735

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChild Mortality; Azithromycin
    InterventionAzithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis

    NCT04454151 · start 2020-08-01

    Registered record
    Registry ID
    NCT04454151
    Conditions
    Familial Adenomatous Polyposis
    Interventions
    Azithromycin Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2022-04-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Adenomatous Polyposis
    InterventionAzithromycin Tablets
    PhasePhase 4
    Registry statusUnknown

  • Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore

    NCT04871633 · start 2020-08-01

    Registered record
    Registry ID
    NCT04871633
    Conditions
    COVID-19
    Interventions
    Remdesivir; Conventional
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-08-01
    Completion
    2020-12-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionRemdesivir; Conventional
    PhaseNot applicable
    Registry statusCompleted

  • Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients

    NCT04502342 · start 2020-06-01

    Registered record
    Registry ID
    NCT04502342
    Conditions
    Covid19
    Interventions
    Hydroxycloroquine and Azythromycine; Cospherunate/Azythromycine; Cospherunate/Phytomedicine/Azythromycien
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-06-01
    Completion
    2020-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionHydroxycloroquine and Azythromycine; Cospherunate/Azythromycine; Cospherunate/Phytomedicine/Azythromycien
    PhasePhase 2
    Registry statusUnknown

  • Treatment for COVID-19 in High-Risk Adult Outpatients

    NCT04354428 · start 2020-04-16

    Registered record
    Registry ID
    NCT04354428
    Conditions
    COVID-19; SARS-CoV-2
    Interventions
    Ascorbic Acid; Hydroxychloroquine Sulfate; Azithromycin; Folic Acid; Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2020-04-16
    Completion
    2020-11-30
    Enrolment
    289

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; SARS-CoV-2
    InterventionAscorbic Acid; Hydroxychloroquine Sulfate; Azithromycin; Folic Acid +1 more
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Patient Preference Trial for COVID-19 (PPT-COVID)

    NCT04418193 · start 2020-04-06

    Registered record
    Registry ID
    NCT04418193
    Conditions
    Coronavirus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2020-04-06
    Completion
    2021-02-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients

    NCT04371406 · start 2020-04

    Registered record
    Registry ID
    NCT04371406
    Conditions
    Covid-19
    Interventions
    Hydroxychloroquine and Azithromycin; Azinc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-04
    Completion
    2020-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19
    InterventionHydroxychloroquine and Azithromycin; Azinc
    PhasePhase 3
    Registry statusWithdrawn